CDK9 As a New Therapeutic Vulnerability for Ibrutinib Resistance Mantle Cell Lymphoma (MCL)

被引：0
|
作者：
Wang, Michelle
Zhao, Xiaohong
Jiang, Huijuan
Yan, Joy Catherine
Sotomayor, Eduardo
Shain, Kenneth H.
Shah, Bijal
Tao, Jianguo
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141386
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Ibrutinib as bridge therapy to allogeneic stem cell transplantation in refractory mantle cell lymphoma (MCL): A case report
    Grillo, G.
    Zucchetti, E.
    Zilioli, V. R.
    Rusconi, C.
    Forno, B.
    Zancanella, M.
    Meli, E.
    Minga, P.
    Cairoli, R.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S169 - S169
  • [42] Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL).
    Epperla, Narendranath
    Hamadani, Mehdi
    Ahn, Kwang Woo
    Oak, Eunhye
    Cashen, Amanda F.
    Kanate, Abraham Sebastian
    Calzada, Oscar
    Farmer, Zachary Luke
    Tallarico, Michael
    Nabhan, Chadi
    Costa, Luciano J.
    Kenkre, Vaishalee Padgaonkar
    Ghosh, Nilanjan
    Cohen, Jonathon Brett
    Hari, Parameswaran
    Fenske, Timothy S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Ibrutinib maintenance following induction for untreated mantle cell lymphoma (MCL): Initial safety report.
    Karmali, Reem
    Abramson, Jeremy S.
    Stephens, Deborah Marie
    Barnes, Jeffrey A.
    Kaplan, Jason B.
    Winter, Jane N.
    Ma, Shuo
    Petrich, Adam Matthew
    Hochberg, Ephraim P.
    Takvorian, Tak
    Nelson, Valerie
    Gordon, Leo I.
    Pro, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
    Zhao, Xiaohong
    Wang, Michelle Y.
    Jiang, Huijuan
    Lwin, Tint
    Park, Paul M.
    Gao, Jing
    Meads, Mark B.
    Ren, Yuan
    Li, Tao
    Sun, Jiao
    Fahmi, Naima Ahmed
    Singh, Satishkumar
    Sehgal, Lalit
    Wang, Xuefeng
    Silva, Ariosto S.
    Sotomayor, Eduardo M.
    Shain, Kenneth H.
    Cleveland, John L.
    Wang, Michael
    Zhang, Wei
    Qi, Jun
    Shah, Bijal D.
    Tao, Jianguo
    CELL REPORTS, 2021, 34 (11):
  • [45] New therapeutic strategies for mantle cell lymphoma
    Yamamoto, Kazuhito
    ANNALS OF ONCOLOGY, 2018, 29
  • [46] The Development of a Precision Medicine Platform to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
    Liu, Yang
    Zhao, Shuangtao
    Jiang, Changying
    Yao, Yixin
    Murfin, Kelley Paige
    Grundman, Hadley
    Zhang, Liang
    Nomie, Krystle
    Wang, Linghua
    Wang, Michael
    BLOOD, 2019, 134
  • [47] Ibrutinib-a new standard treatment for relapsed mantle cell lymphoma?
    Martin, Peter
    LANCET, 2016, 387 (10020): : 728 - 729
  • [48] HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma
    Jacobson, Caron
    Kopp, Nadja
    Layer, Jacob V.
    Redd, Robert A.
    Tschuri, Sebastian
    Haebe, Sarah
    van Bodegom, Diederik
    Bird, Liat
    Christie, Amanda L.
    Christodoulou, Alexandra
    Saur, Amy
    Tivey, Trevor
    Zapf, Stefanie
    Bararia, Deepak
    Zimber-Strobl, Ursula
    Rodig, Scott J.
    Weigert, Oliver
    Weinstock, David M.
    BLOOD, 2016, 128 (21) : 2517 - 2526
  • [49] Targeting CDK9 with a novel potent and selective inhibitor, YX0798, in CAR-Trelapsed mantle cell lymphoma models
    Jiang, Vivian
    Xue, Yu
    Kim, Hong
    McIntosh, Joseph
    Chen, Haiying
    Zhang, Tianci
    Liu, Yang
    Zhou, Jia
    Wang, Michael
    CANCER RESEARCH, 2024, 84 (06)
  • [50] Mantle cell lymphoma of the iris treated by ibrutinib
    De Gauzy, T. Sales
    Oberic, L.
    Fournie, P.
    Soler, V.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2018, 41 (10): : E501 - E502
12345